Insights

Why the CSL (ASX:CSL) share price is rising and could keep climbing

The CSL Limited (ASX:CSL) share price is rising on Tuesday and could keep on climbing according to leading brokers. Here’s why…
The post Why the CSL (ASX:CSL) share price is rising and could keep climbing appeared first on The Motley Fool Australia. –

The CSL Limited (ASX: CSL) share price is pushing higher on Tuesday morning.

At the time of writing, the biotherapeutics giant’s shares are up 1% to $292.00.

Why is the CSL share price rising today?

The CSL share price was given a boost by a broker note out of the Macquarie Group Ltd (ASX: MQG) equities desk this morning.

According to the note, the broker has retained its outperform rating and $312.00 price target on the company’s shares.

This price target implies potential upside of approximately 7% over the next 12 months.

What did Macquarie say?

Macquarie has been leveraging Google data to track foot traffic at the company’s network of plasma collection centres during the pandemic.

Positively, the latest data indicates that foot traffic has now risen to the highest level since Macquarie began tracking it. This coincides with a reduction in new COVID-19 cases in the US and the successful rollout of vaccines across the country.

Macquarie’s analysts believe this improving collections data is supportive of its immunoglobulin revenue and earnings growth forecasts.

In addition to this, the broker notes that CSL’s new plasmapheresis platform, which is being developed with Terumo Blood and Cell Technologies, has the potential to lift yields meaningfully.

The broker believes the innovative plasma collection platform could increase yields by 10% per donation in the future, which would give its gross profit a big boost if granted regulatory approval.

Who else is bullish?

Macquarie isn’t the only broker that is positive on the CSL share price. A number of other brokers also have the equivalent of buy ratings on its shares.

For example, Credit Suisse has an outperform rating and $315.00 price target on its shares and UBS has a buy rating and $330.00 price target.

The latter implies potential upside of 13% for the CSL share price over the next 12 months.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

*Returns as of February 15th 2021

More reading

An ASX investor’s guide to ESG-focused ETFs

Expert says buy these ASX expensive defensives as market momentum is peaking

Is the CSL (ASX:CSL) share price good value?
ASX 200 Weekly Wrap: ASX whipsaws in volatile week

2 five-star ASX shares that analysts love

The post Why the CSL (ASX:CSL) share price is rising and could keep climbing appeared first on The Motley Fool Australia.

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
Trade The US Market With ZERO Brokerage* + FREE Access To Trading Ideas & Value Analysis Tools. Click Here!